Amarantus Bioscience Holdings Inc (AMBS)

[WarpCore61]

Since that trial wasn't originally initiated as a retrospective study, the biases you've claimed related to that type of study shouldn't be present. While it is retrospective in the sense it is looking back at known data, the fact those biases aren't present should give significant value to the data generated.

It is clear the original trial in 2005 was a prospective study. The current study is certainly retrospective as it is not generating new data but looking back at data already existing from the original trial and the outcomes of the trial subjects over the years.

By the way, I don't agree with your statement:

I expect that no stone will remain unturned, including MANF for PD despite the total failure of other NFs in their treatment of PD to date.

This video clearly shows the effectiveness of NFs in Parkinson's treatment, GDNF in this case.

While there was an indication of the placebo effect in this trial, there is additional data that indicates the GDNF treatment resulted in 30% neuron regrowth in the SN area. And we all know about the delivery issues with the catheter technology at the time of this study. The fact that GDNF has been shown to have significant effect on Parkinson's patients, and that MANF is superior to GDNF in animal trials, there is still the potential that MANF may be a curative treatment for PD, given the improved delivery methods as compared to the original study.